Indication
Histiocytosis
3 clinical trials
3 products
Product
BDTX-4933Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive NeoplasmsStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisStatus: Recruiting, Estimated PCD: 2026-03-30
Product
VemurafenibClinical trial
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With HistiocytosisStatus: Recruiting, Estimated PCD: 2026-03-30
Product
fluorodeoxyglucose